Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today

By Brian Orelli, PhD - Feb 3, 2020 at 2:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead Sciences may be winning the race to develop the first coronavirus treatment.

What happened

Shares of Inovio Pharmaceuticals (INO -5.03%) and Vir Biotechnology (VIR -1.55%), two companies developing drugs for the coronavirus outbreak in China, are down today on word that Gilead Sciences (GILD -0.21%) looks to have beaten the companies to the punch, setting up a research collaboration with Chinese authorities to run a clinical trial for its antiviral medication remdesivir.

As of 1:46 p.m. EST on Monday, Inovio had fallen 14.5%, while Vir was down 16.2%.

People on the sidewalk wearing face masks

Image source: Getty Images.

So what

While the news that Gilead has moved first is disappointing for the biotechs, there may still be a need for Inovio's 2019-nCoV coronavirus vaccine. Remdesivir might lessen the symptoms of the virus, but it won't stop the spread of the disease in mildly symptomatic patients who aren't likely to take the drug.

Vir's antibody treatment would likely compete more directly with remdesivir since it would attack the virus directly and would likely be used to treat infected patients.

Both Inovio and Vir increased in value quite a bit in January. Vir doubled, while Inovio was up almost 40% as the 2019-nCoV coronavirus outbreak has spread and investors pinned hopes on the potential to develop drugs for the virus. With the valuations already incorporating some of the potential, it's not surprising to see a pullback on news that the opportunity might not be as large as first imagined.

Now what

The bigger issue for Inovio and Vir is how long the clinical trial process could end up taking and whether the outbreak will peter out before the companies can get their treatments to market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.89 (-5.03%) $0.10
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
$22.28 (-1.55%) $0.35
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.24 (-0.21%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.